News >

FDA Approves Dabrafenib/Trametinib Combo for BRAF+ NSCLC

Jason Harris
Published: Thursday, Jun 22, 2017

Bruno Strigini, CEO

Bruno Strigini

The FDA approved the combination of dabrafenib (Tafinlar) and trametinib (Mekinist) for patients with BRAF V600–positive advanced or metastatic non–small cell lung cancer (NSCLC).

V600 mutation.
  1. Planchard D, Besse B, Groen HJM, et al. An open-label phase II trial of dabrafenib (D) in combination with trametinib (T) in patients (pts) with previously treated BRAF V600E–mutant advanced non-small cell lung cancer (NSCLC; BRF113928). J Clin Oncol. 2016;34 (suppl; abstr 107).
  2. Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial [published online June 6, 2016]. Lancet Oncol. DOI: 10.1016/S1470-2045(16)30146-2.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication